Seeking Alpha

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm...

UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm believes the pullback following the company's disappointing Q1 results is due to transient issues, and the company is still on track for Q2. The firm maintains its buy rating on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|